Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non Operating Income (2020 - 2025)

Mirum Pharmaceuticals has reported Other Non Operating Income over the past 6 years, most recently at -$218000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$218000.0 for Q4 2025, down 194.37% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 95.47% YoY), and the annual figure for FY2025 was $2.4 million, up 95.47%.
  • Other Non Operating Income for Q4 2025 was -$218000.0 at Mirum Pharmaceuticals, down from $395000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for MIRM hit a ceiling of $2.1 million in Q1 2025 and a floor of -$49.3 million in Q4 2023.
  • Median Other Non Operating Income over the past 5 years was -$17000.0 (2021), compared with a mean of -$5.6 million.
  • Biggest five-year swings in Other Non Operating Income: surged 2247.06% in 2022 and later tumbled 13610.41% in 2023.
  • Mirum Pharmaceuticals' Other Non Operating Income stood at -$17000.0 in 2021, then surged by 2247.06% to $365000.0 in 2022, then tumbled by 13610.41% to -$49.3 million in 2023, then skyrocketed by 100.47% to $231000.0 in 2024, then plummeted by 194.37% to -$218000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$218000.0 (Q4 2025), $395000.0 (Q3 2025), and $86000.0 (Q2 2025) per Business Quant data.